JPWO2020212416A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020212416A5
JPWO2020212416A5 JP2021560972A JP2021560972A JPWO2020212416A5 JP WO2020212416 A5 JPWO2020212416 A5 JP WO2020212416A5 JP 2021560972 A JP2021560972 A JP 2021560972A JP 2021560972 A JP2021560972 A JP 2021560972A JP WO2020212416 A5 JPWO2020212416 A5 JP WO2020212416A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
cancer
breast cancer
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021560972A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022530339A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/060582 external-priority patent/WO2020212416A1/fr
Publication of JP2022530339A publication Critical patent/JP2022530339A/ja
Publication of JPWO2020212416A5 publication Critical patent/JPWO2020212416A5/ja
Pending legal-status Critical Current

Links

JP2021560972A 2019-04-15 2020-04-15 インテグリンα１０および侵攻性癌型 Pending JP2022530339A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19169233.4 2019-04-15
EP19169233 2019-04-15
PCT/EP2020/060582 WO2020212416A1 (fr) 2019-04-15 2020-04-15 Intégrine alpha10 et formes de cancer agressives

Publications (2)

Publication Number Publication Date
JP2022530339A JP2022530339A (ja) 2022-06-29
JPWO2020212416A5 true JPWO2020212416A5 (fr) 2023-04-21

Family

ID=66349286

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021560972A Pending JP2022530339A (ja) 2019-04-15 2020-04-15 インテグリンα１０および侵攻性癌型

Country Status (12)

Country Link
US (1) US20220177591A1 (fr)
EP (1) EP3956360A1 (fr)
JP (1) JP2022530339A (fr)
KR (1) KR20210151901A (fr)
CN (1) CN114585643A (fr)
AU (1) AU2020257528A1 (fr)
BR (1) BR112021020536A2 (fr)
CA (1) CA3136840A1 (fr)
IL (1) IL287009A (fr)
MX (1) MX2021012644A (fr)
SG (1) SG11202110729TA (fr)
WO (1) WO2020212416A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023166170A1 (fr) 2022-03-03 2023-09-07 Targinta Ab Anticorps anti-intégrine alpha10
WO2024047172A1 (fr) 2022-08-31 2024-03-07 Targinta Ab Conjugué anticorps-médicament d'intégrine alpha10

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2324381C (fr) 1998-04-02 2013-02-26 Cartela Ab Heterodimere d'integrine et sous-unite de cet heterodimere
EP1496886A1 (fr) 2002-04-12 2005-01-19 Cartela AB Souris inactivees et leur utilisation
WO2007107774A2 (fr) * 2006-03-22 2007-09-27 Cartela R & D Ab Nouvelles méthodes de diagnostic et de traitement
WO2008075038A1 (fr) * 2006-12-18 2008-06-26 Bioinvent International Ab Agent de liaison à la sous unité alpha-11 de l'intégrine
US9181553B2 (en) * 2011-06-06 2015-11-10 Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Method of treatment of breast cancers over-expressing the SHP2 signature genes
ES2902420T3 (es) * 2013-05-13 2022-03-28 Univ Tufts Composiciones para el tratamiento del cáncer que expresa ADAM8
US9765146B2 (en) * 2014-08-22 2017-09-19 Sorrento Therapeutics, Inc. Fully human anti-CXC chemokine receptor 5 (CXCR5) antibodies
KR102571075B1 (ko) * 2015-02-16 2023-08-25 타르진타 아베 Cns에서 악성 종양의 검출 및 치료
AU2016252771B2 (en) * 2015-04-22 2021-12-16 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells

Similar Documents

Publication Publication Date Title
Fan et al. Therapeutic application of anti-growth factor receptor antibodies
US9695250B2 (en) Pharmaceutical compositions with resistance to soluble CEA
US7939072B2 (en) Anti-EGFR antibodies with an improved anti-tumor activity and compositions and articles of manufacture comprising same
KR101885705B1 (ko) 종양 개시 세포를 인지하는 항체와 항원 및 이의 용도
CA2747064C (fr) Anticorps monoclonaux diriges contre le domaine lg4-5 de la chaine alpha3 de la laminine-5 humaine
KR20110047698A (ko) ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그의 용도
RU2011115117A (ru) Нацеленные средства связывания, направленные на dll4, и их применение
JP2008537673A5 (fr)
CA2959671C (fr) Anticorps anti-ck8 destines a etre utilises dans le traitement de cancers
US10246507B2 (en) Polypeptide, anti-VEGF antibody, and anti-c-Met/anti-VEGF bispecific antibodies comprising the same
Kato-Nakano et al. Characterization and evaluation of the antitumour activity of a dual-targeting monoclonal antibody against claudin-3 and claudin-4
KR20220041848A (ko) Claudin 18.2에 대한 항체와 면역 체크포인트 억제제를 포함하는 암 치료를 위한 병용 요법
KR20180054492A (ko) CD66c에 특이적으로 결합하는 항체 및 그의 용도
KR102107963B1 (ko) 탄산탈수소 효소에 결합하는 항체 및 이의 용도
Wang et al. A novel 5T4-targeting antibody-drug conjugate H6-DM4 exhibits potent therapeutic efficacy in gastrointestinal tumor xenograft models
Morita et al. Humanized anti-CD271 monoclonal antibody exerts an anti-tumor effect by depleting cancer stem cells
EP2400983B1 (fr) Utilisation d'anticorps monoclonaux anti-90k pour la prévention et le traitement de tumeurs et des métastases de celles-ci
Capone et al. Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma
US10975160B2 (en) Antibody binding to carbonic anhydrase and use thereof
KR20130079219A (ko) 면역원성이 제거된 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
Watanabe et al. In vitro and in vivo antitumor effects of recombinant bispecific antibodies based on humanized anti-EGFR antibody
JPWO2020212416A5 (fr)
Wang et al. Construction of a novel TROP2/CD3 bispecific antibody with potent antitumor activity and reduced induction of Th1 cytokines
EP3880706A1 (fr) Anticorps bispécifiques dirigés contre 90k humain, et soit l'endosialine, soit her3
JPWO2020081928A5 (fr)